Short Communication

Plasma levels of Semaphorin 4D are decreased by adjuvant tamoxifen but not aromatase inhibitor therapy in breast cancer patients

Andy Göbel\textsuperscript{b,b,⁎}, Jan D. Kuhlmann\textsuperscript{b,c,d}, Theresa Link\textsuperscript{b,c,d}, Pauline Wimberger\textsuperscript{b,c,d}, Cornelia Link-Rachner\textsuperscript{e}, Stefanie Thiele\textsuperscript{a,b}, Stefania Dell’Endice\textsuperscript{a}, Giulia Furesi\textsuperscript{a}, Dorit Breining\textsuperscript{a,b}, Martina Rauner\textsuperscript{a}, Lorenz C. Hofbauer\textsuperscript{a,b,f}, Tilman D. Rachner\textsuperscript{a,b,f}

\textsuperscript{a} Division of Endocrinology, Diabetes and Bone Diseases, Department of Medicine III, TU Dresden Medical Center, Fetscherstraße 74, D-01307 Dresden, Germany
\textsuperscript{b} German Cancer Consortium (DKTK), partner site Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany
\textsuperscript{c} Department of Gynecology and Obstetrics, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
\textsuperscript{d} National Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, Germany
\textsuperscript{e} Division of Hematology and Oncology, Department of Medicine I, Technische Universität Dresden, Germany
\textsuperscript{f} Center for Healthy Aging, Technische Universität Dresden, Dresden, Germany

Keywords: Breast cancer, Semaphorin 4D, Tamoxifen, Aromatase inhibitors

ARTICLE INFO

ABSTRACT

Background: Semaphorin 4D (Sema4D) is a glycoprotein that inhibits bone formation and has been associated with cancer signaling and the occurrence of bone metastases. Recently, Sema4D expression has been linked to estrogen signaling in breast cancer. Endocrine therapies like tamoxifen and aromatase inhibitors (AI) are a standard therapeutic approach in hormone receptor positive breast cancers. Tamoxifen exerts estrogenic effects on bone, whereas AI negatively affect bone health by increasing resorption and fracture risk. The effect of endocrine therapies on circulating Sema4D levels in breast cancer patients has not been investigated yet.

Methods: We measured circulating Sema4D plasma levels at primary diagnosis and in a follow-up sample 12 months after surgery in a cohort of 46 pre- and postmenopausal women with primary estrogen receptor positive breast cancer receiving adjuvant tamoxifen or AI.

Results: The mean baseline levels ± SD for Sema4D were 441.6 ± 143.4 pmol/l. No significant differences in total plasma Sema4D were observed when stratifying the patients according to age, menopausal status, tumor subtype, nodal and hormone receptor status, or tumor size. However, Sema4D levels were significantly reduced by 28% (p < 0.001) in tamoxifen treated patients 12 months after surgery, whereas no alteration was observed in patients treated with AI.

Conclusion: This finding potentially represents an additional mechanism of the bone-protective properties of tamoxifen and further emphasizes a link between Sema4D and estrogen receptor signaling.

1. Introduction

Semaphorin 4D (Sema4D) is a transmembrane homodimer glycoprotein and member of the Semaphorin family which consists of more than 20 genes. Originally, Sema4D was identified as a major immune regulator [1]. In addition, several studies revealed that Sema4D is associated with bone remodeling and cancer progression. The protein is abundantly expressed by differentiating osteoclasts, binds its receptor Plexin-B1 on osteoblasts and inhibits osteoblastic function by suppressing insulin-like growth factor-1 (IGF-1). In mice, a global knockout of Sema4D leads to an increased bone volume and the antibody-mediated neutralization of Sema4D in an osteoblast-osteoclast co-culture increases osteoblastic bone formation [2]. In addition osteoclasts with knocked-out Sema4D display a significant bone resorption defect [3]. Interestingly, elevated levels of soluble Sema4D are found in the serum and bone marrow of multiple myeloma patients, a malignant disease that is accompanied by the presence of osteolytic bone lesions [4]. In ovarian cancer, Sema4D is upregulated in human cell lines. In these cells, the ERα was shown to accelerate tumor cell proliferation at least partially by positive regulation of Sema4D. In addition, Sema4D is increased in the serum of affected patients with ovarian cancer [5]. In addition, Plexin-B1 is overexpressed in primary prostate cancer tissue [6].
Sema4D signaling is involved in tumor angiogenesis as Plexin-B1 is highly expressed in endothelial cells [7]. A supportive role of Sema4D in tumor progression was further revealed by showing that its neutralization promotes immune cell infiltration into the tumor microenvironment and shifts the immune response towards a pronounced pro-inflammatory and antitumor milieu [8]. In breast cancer, the role of Sema4D signaling appears increasingly complex. While the knock-out of Sema4D in breast cancer cell lines suppressed xenograft growth and angiogenesis [9] and decreased the occurrence of bone metastases [10], a reduced expression of Sema4D has also been described to be associated with a poor prognosis [11]. An increased expression of Sema4D has been described in estrogen receptor positive breast tumors and Sema4D was up-regulated in estrogen receptor (ER) positive breast cancer cell lines, following the exposure to ER agonists [11].

In this study we aimed to investigate i) whether baseline Sema4D levels differ among breast cancer patients with different clinical characteristics and ii) if the adjuvant treatment of breast cancer patients with tamoxifen or aromatase inhibitors (AI) affects the levels of circulating Sema4D.

2. Patients and methods

2.1. Patient population, patient characteristics and study design

In this study 46 consecutive patients with histologically confirmed early invasive breast cancer who underwent surgical treatment at the Department of Gynecology and Obstetrics at the University Hospital Dresden, Germany between 2013 and 2014 were included [12]. Patients had not received any prior treatment at the time of inclusion. Informed written consent was obtained from all patients. The study was approved by the Institutional Review Board (Dresden EK 236,082,012) and performed according to the declaration of Helsinki. Inclusion criteria were early disease with no sign of metastases and confirmed tumor expression of the ER. Patients with neoadjuvant treatment were excluded. Surgical procedures were breast conserving surgery or mastectomy. Adjuvant (anthracycline and taxane based) chemotherapy was given in 57% of cases with a higher risk of relapse. Radiation therapy was performed in 85% of the patients. Adjuvant endocrine therapy was performed in all patients with either tamoxifen (29/46; 63%) or an aromatase inhibitor (exemestane, letrozole, and anastrozole; 17/44; 39%). We considered women perimenopausal when they were 40 years or older and were premenopausal before chemotherapy treatment but neither clearly pre- nor postmenopausal afterwards. Patients were treated according to standard guidelines (AGO 2013). Her2 positive breast cancer patients (6/46; 13%) were treated with trastuzumab.

2.2. Plasma sampling

Blood was drawn at primary diagnosis before any treatment, and one year after primary surgery. Nine ml blood were obtained from each patient with a EDTA S-Monovette® (Sarstedt AG & Co., Nuembrecht, Germany), directly stored at 4 °C and processed within 4 h to avoid blood cell lysis. Blood was fractionated by centrifugation for 8 min at 1800 × g at room temperature. Afterwards, the plasma fraction was removed and stored at −80 °C until analyses for Sema4D were performed.

2.3. Measurement of soluble Semaphorin 4D by ELISA

Human soluble Sema4D plasma concentrations were measured by ELISA (Biomedica, Vienna, Austria). Briefly, 10 µl of undiluted plasma were mixed with 100 µl of assay buffer on coated microtiter strips. After 3 h at room temperature, wells were washed and conjugate was added to each well. After another hour, wells were washed again and 100 µl of substrate was added to each well. After 30 min of incubation, the stop solution was added and the absorbance was measured immediately at 450 nm with reference at 630 nm.

2.4. Statistics

For the comparison of Sema4D levels within the patient cohort, baseline levels were analyzed for the whole patient cohort and after stratifying the patients according to clinical parameters and treatment groups. Mean ± SD was calculated and compared between the groups using one-way ANOVA (Table 2). For the comparison of Sema4D time-course levels in the two treatment groups, data are presented as box-whisker plots of absolute values of Sema4D at two time points in both the AI and tamoxifen group and as absolute and relative differences of Sema4D levels 12 months after diagnosis compared to basal levels before surgery. Absolute and relative changes of Sema4D over time are additionally presented as median. Outliers were determined via Grubb’s test. Single group comparisons were performed by a Student’s t-test and group analyses were performed using one-way analysis of variance (ANOVA) by GraphPad Prism 6.03 (GraphPad, La Jolla, CA, USA). P-values < 0.05 were considered statistically significant. Final arrangement of the figures was performed using CorelDraw® X6 version 16.0.0.707.

3. Results

3.1. Patient cohort

The cohort consisted of 46 breast cancer patients as previously described [12]. Baseline patient characteristics at the time of primary diagnosis are shown in Table 1. The median age was 61 (range 26–85 years) and the median weight 75 kg (range 50–115 kg). The majority of patients (67%) were postmenopausal. The most predominant tumor type was Luminal A (71.7%), 15.2% were luminal B Her2 negative and 13% were classified as Luminal B Her2 positive. Only ER positive tumors were included. Of these, 93.5% displayed a concurrent expression of the progesterone receptor (PR). Tumors of 6 patients (13%) showed positive Her2 expression. The majority of the patients had T1 tumors (36/46, 78.3%), 6 patients had T2 tumors (13%), and 4 patients had T3/T4 tumors (8.7%). Of all patients, 71.7% (33/46) were lymph node negative. Patients received adjuvant therapy with either tamoxifen (29/46; 63%) or AI (17/46; 37%). AI are only prescribed in postmenopausal women. Hence, the mean age of the aromatase inhibitor group was significantly higher than the tamoxifen treated group (66.5 ± 8.1 vs. 55.5 ± 11.1; p = 0.0009).

3.2. Baseline levels of soluble Semaphorin 4D

At primary diagnosis, the mean baseline levels ± SD for Sema4D in the total cohort were 441.6 ± 143.4 pmol/l. All patients were then stratified according to age, menopausal status, tumor subtype, nodal status, PR/Her2 status and tumor size and mean baseline levels of Sema4D compared (Table 2). No significant differences of Sema4D plasma level were observed between patients with different tumor subtype, nodal status or tumor size. In addition, age, menopausal status or Her2/PR-positivity did not have a significant association with plasma Sema4D levels. Patients were additionally stratified according to their future endocrine treatment after surgery (AI or tamoxifen). When comparing the AI vs. tamoxifen group within clinical parameters, Sema4D levels in patients with Luminal B Her2 negative tumors in the tamoxifen group was significantly higher than in patients with Luminal A or Luminal B Her2 positive tumors in the aromatase inhibitor group (p ≤ 0.05).

3.3. Effect of adjuvant endocrine therapy on Semaphorin 4D levels

We next analyzed the effects of adjuvant tamoxifen or AI treatment on plasma Sema4D by comparing the respective plasma levels at
A. Göbel, et al.  
Journal of Bone Oncology 16 (2019) 100237

Table 1
Baseline patient characteristics.

|                         | All (n = 46) | AI (n = 17) | Tamoxifen (n = 29) | p-value AI vs. Tamoxifen |
|-------------------------|--------------|-------------|---------------------|--------------------------|
| Age, years (median; range) | 61 (26–85)   | 66 (51–85)  | 52 (26–72)          |                          |
| Age, years (mean ± SD)   | 60 ± 11.4    | 66.5 ± 8.1  | 55.5 ± 11.1         | 0.009                    |
| <60; n (%)               | 22 (47.8)    | 3 (17.6)    | 19 (65.5)           |                          |
| ≥60; n (%)               | 24 (52.2)    | 14 (82.4)   | 10 (34.5)           |                          |
| Weight, kg (median; range) | 75 (50–115)  | 71 (60–105) | 75 (50–115)         |                          |
| Weight, kg (mean ± SD)   | 77 ± 15.7    | 76 ± 15.4   | 77.8 ± 16.1         |                          |
| Menopausal status; n (%) |              |             |                     |                          |
| Premenopausal            |              |             |                     |                          |
| Perimenopausal           |              |             |                     |                          |
| Postmenopausal           |              |             |                     |                          |
| ER status; n (%)         |              |             |                     |                          |
| positive                 |              |             |                     |                          |
| negative                 |              |             |                     |                          |
| PR status; n (%)         |              |             |                     |                          |
| positive                 |              |             |                     |                          |
| negative                 |              |             |                     |                          |
| Her2 status; n (%)       |              |             |                     |                          |
| positive                 |              |             |                     |                          |
| negative                 |              |             |                     |                          |
| Tumor subtype; n (%)     |              |             |                     |                          |
| Luminal A                |              |             |                     |                          |
| Luminal B Her2 negative  |              |             |                     |                          |
| Luminal B Her2 positive  |              |             |                     |                          |
| Tumor size; n (%)        |              |             |                     |                          |
| pT1                      |              |             |                     |                          |
| pT2                      |              |             |                     |                          |
| pT3-4                    |              |             |                     |                          |
| Nodal status; n (%)      |              |             |                     |                          |
| Node positive            |              |             |                     |                          |
| Node negative            |              |             |                     |                          |

ER = estrogen receptor; PR = progesterone receptor.  
Her2 = human epidermal growth factor receptor 2.

primary diagnosis and after one year. Assessment one year after surgery revealed a significant decrease of Sema4D levels in patients treated with tamoxifen (464.4 ± 159 pmol/l vs. 335.8 ± 89.8 pmol/l; −27.7%;p<0.001), while there were no significant changes in the aromatase inhibitor treated group (402.6 ± 110.7 pmol/l vs. 413 ± 128.4 pmol/l; +2.6%; Fig. 1a and b). The results were reflected by the difference of Sema4D levels in both the tamoxifen and AI group between the two time points (one year after surgery vs. −1 day before surgery). Here, total and relative median levels of Sema4D plasma level differences were reduced in the tamoxifen group but not in the AI

Table 2
Baseline levels of Semaphorin 4D.

|                         | All (pmol/l) | p-value all | AI (pmol/l) | Tamoxifen (pmol/l) | p-value AI vs. Tamoxifen |
|-------------------------|--------------|-------------|-------------|---------------------|--------------------------|
| All                     | 441.6 ± 143.4| 402.6 ± 107.4| 464.4 ± 156.3| ns                  |
| Age, years              |              |             |             |                     |                          |
| <60                     | 438.1 ± 132.0| 400.8 ± 111.5| 443.9 ± 130.5| ns                  |
| ≥60                     | 444.8 ± 132.0| ns          | 403.0 ± 106.5| 503.3 ± 190.1      |
| Menopausal status       |              |             |             |                     |                          |
| Premenopausal           | 470.7 ± 155.2| –           | 470.7 ± 147.2| ns                  |
| Perimenopausal          | 421.0 ± 113.9| –           | 421.0 ± 101.9| ns                  |
| Postmenopausal          | 435.5 ± 148.9| ns          | 402.6 ± 107.4| 475.4 ± 174.8      |
| PR status               |              |             |             |                     |                          |
| positive                | 445.6 ± 146.7| 411.3 ± 106.3| 463.9 ± 159.0| ns                  |
| negative                | 384.3 ± 123.0| ns          | 337.5 ± 92.6 | 447.8 ± 0*         |
| Her2 status             |              |             |             |                     |                          |
| positive                | 410.2 ± 131.5| 493.3 ± 0   | 393.6 ± 125.0 | ns                  |
| negative                | 446.3 ± 147.8| ns          | 396.9 ± 108.2| 479.2 ± 158.1      |
| Tumor subtype           |              |             |             |                     |                          |
| Luminal A²              | 428.6 ± 119.6| 410.9 ± 106.4| 441.7 ± 123.8| 0.03 (AI² vs. TAM²) |
| Luminal B Her2 negative³| 529.4 ± 236.6| 299.2 ± 59.3| 621.5 ± 190    |
| Luminal B Her2 positive³| 410.2 ± 131.5| ns          | 493.3 ± 0*    | 393.6 ± 125        |
| Tumor size              |              |             |             |                     |                          |
| pT1                     | 437.7 ± 151.6| 383.8 ± 90.9 | 464.7 ± 165   | ns                  |
| pT2                     | 500.0 ± 112.6| 521.3 ± 90.9 | 478.7 ± 109.3| ns                  |
| pT3-4                   | 388.5 ± 122.1| ns          | 337.5 ± 92.6 | 439.4 ± 92.8       |
| Nodal status            |              |             |             |                     |                          |
| Node positive           | 436.4 ± 112.9| 441.2 ± 122.5| 432.2 ± 94.5 | ns                  |
| Node negative           | 443.6 ± 157.3| ns          | 381.5 ± 91.5 | 474.7 ± 170        |

ER = estrogen receptor; PR = progesterone receptor.  
Her2 = human epidermal growth factor receptor 2.
group. (Fig. 1c; p < 0.01). All patients treated with AI were post-menopausal. In the tamoxifen group, patients had varying menopausal status ranging from pre- (9/28), peri- (5/28) to postmenopausal (14/28). To exclude any effects mediated by menopausal or tumor type status, we stratified the tamoxifen group according to menopausal status or tumor type and depicted the Sema4D differences to baseline (Fig. 2). Here, no significant differences were observed between the groups.

4. Discussion

Maintaining long-term bone health in patients with breast cancer is an important issue in their clinical management. First, breast cancer cells show a high propensity to metastasize to bone where they establish osteolytic lesions in the majority of patients in advanced stages of the disease [13,14]. In addition, anti-hormonal therapies may negatively affect bone as they lead to a deprivation of bone protective estrogen and cancer treatment-induced bone loss [15]. It is widely recognized that AI and tamoxifen exert different effects on bone. AI are inhibitors of the aromatase enzyme, which is important for the conversion of estrogens from androgens in peripheral tissues including fat and breast. AI are used in postmenopausal women with hormone receptor positive breast cancer to block residual estrogen levels [16]. Hence, AI have deleterious effects on bone health [17]. By contrast, tamoxifen is a selective estrogen receptor modulator (SERM) with partial ER-agonistic and antagonistic functions, depending on the cell type [18]. In bone, tamoxifen is a partial ER-agonist and reduces bone turnover and loss in postmenopausal women [19,20]. The divergent effects of tamoxifen and AI have been described in a number of studies [21,22].

Tamoxifen is considered bone protective in postmenopausal women. As it mimics the actions of estrogen in bone, it inhibits osteoclast formation and bone resorption while osteoclastic apoptosis is increased [23–25]. Using the same cohort as in this study, we have recently revealed that adjuvant tamoxifen significantly reduced the serum levels of Dickkopf-1 (DKK-1) [12]. DKK-1 is an inhibitor of the Wnt pathway and suppresses osteoblastic differentiation thereby representing a negative player of bone formation [12]. AI therapy had no effect on serum levels

4. Discussion

Maintaining long-term bone health in patients with breast cancer is an important issue in their clinical management. First, breast cancer cells show a high propensity to metastasize to bone where they establish osteolytic lesions in the majority of patients in advanced stages of the disease [13,14]. In addition, anti-hormonal therapies may negatively affect bone as they lead to a deprivation of bone protective estrogen and cancer treatment-induced bone loss [15]. It is widely recognized that AI and tamoxifen exert different effects on bone. AI are inhibitors of the aromatase enzyme, which is important for the conversion of estrogens from androgens in peripheral tissues including fat and breast. AI are used in postmenopausal women with hormone receptor positive breast cancer to block residual estrogen levels [16]. Hence, AI have deleterious effects on bone health [17]. By contrast, tamoxifen is a selective estrogen receptor modulator (SERM) with partial ER-agonistic and antagonistic functions, depending on the cell type [18]. In bone, tamoxifen is a partial ER-agonist and reduces bone turnover and loss in postmenopausal women [19,20]. The divergent effects of tamoxifen and AI have been described in a number of studies [21,22].

Tamoxifen is considered bone protective in postmenopausal women. As it mimics the actions of estrogen in bone, it inhibits osteoclast formation and bone resorption while osteoclastic apoptosis is increased [23–25]. Using the same cohort as in this study, we have recently revealed that adjuvant tamoxifen significantly reduced the serum levels of Dickkopf-1 (DKK-1) [12]. DKK-1 is an inhibitor of the Wnt pathway and suppresses osteoblastic differentiation thereby representing a negative player of bone formation [12]. AI therapy had no effect on serum levels
of DKK-1. In this study, we show that tamoxifen also reduced plasma levels of Sema4D in patients with hormone receptor positive breast cancer whereas no effect on Sema4D levels was seen in AI treated patients. Different effects of bone-targeted therapies on Sema4D have already described in postmenopausal women suffering from low bone mass. Circulating levels of Sema4D were increased by denosumab, but decreased following treatment with teriparatide [26]. Sema4D is produced by osteoclasts and suppresses IGF-1 signaling in osteoblasts, thereby inhibiting bone formation [2]. Hence, a reduction of circulating Sema4D by adjuvant tamoxifen therapy potentially represents an addition bone-protective property of tamoxifen in breast cancer patients.

The ELISA used in our study does not distinguish between osteoclast-derived and tumor-derived Sema4D. Studies have shown that human estrogen receptor positive breast cancer cell lines are able to express moderate protein levels of Sema4D [9]. However, given that patients in our study receiving tamoxifen in an adjuvant setting were considered tumor free, decreasing levels of Sema4D are more likely to result from effects on the bone microenvironment.

In conclusion, our study revealed a potential additional bone-protective mechanism of tamoxifen in patients with primary breast cancer by inhibition of Sema4D. Future studies are warranted to assess the underlying molecular mechanisms and the potential of Sema4D modulating therapies. Increasing the number of patients with a balanced representation of the heterogeneous phenotypes of human breast cancer may clarify whether specific patient subpopulations specifically benefit from the Sema4D-reducing actions of tamoxifen.

Compliance with ethical standards

Disclosure of potential conflicts of interest

Funding: The work was funded by the Deutsche Forschungsgemeinschaft to AG (GO 3055/1–2, 3-1, and 4-1), MR (RA 1923/5-1) and to LCH (HO 1875/15–1 and 16-1) and to PharmacoMar (PW), Roche (PW, TL), Pfizer, O.G. Wong, T. Nitkunan, I. Oinuma, C. Zhou, V. Blanc, R.S.D. Brown, et al., Flexin-B1 mutations in prostate cancer, Proc. Natl. Acad. Sci. 104 (2007) 19040–19045, J.R. Basile, R.M. Castilho, V.P. Williams, J.S. Guikid, Semaphorin 4D provides a link between axon guidance processes and tumor-induced angiogenesis, PNAS 103 (2006) 9017–9022.

E.E. Evans, A.S. J Jr., H. Bussler, S. Torno, J. Veeraraghavan, C. Reilly, et al., Antibody blockade of Semaphorin 4D promotes immune in H infiltration into tumor and enhances responses to other immunomodulatory therapies, Cancer Immunol. Res. 3 (2015) 689–702.

H. Jiang, C. Chen, Q. Sun, J. Wu, L. Qia, C. Gao, et al., The role of Semaphorin 4D in tumor development and angiogenesis in human breast cancer, Onco Targets Ther. 9 (2016) 5737–5750.

Y. Yang, A. Buhamrah, A. Schneider, Y. Lin, H. Zhou, Semaphorin 4D promotes skeletal metastasis in breast cancer, PLoS One (2016) 1–20.

M.F.A. Malik, L. Ye, W.G. Jiang, Reduced expression of Semaphorin 4D and plexin-B in breast cancer is associated with poorer prognosis and the potential linkage with oestrogen receptor, Oncol. Rep. 34 (2015) 1049–1057.

A. Göbel, J. Kühnmann, L. Link, P. Wimmerber, A. Brownie, M. Rainer, et al., Adjuvant tamoxifen but not aromatase inhibitor therapy decreases serum levels of the Wnt inhibitor dickkopf-1 while not affecting sclerostin in breast cancer patients, Breast Cancer Res. Treat. 164 (2017) 737–742.

K.N. Weihsbecher, T.A. Guise, L.K. McCaulay, Cancer to bone: a fatal attraction, Nat. Rev. Cancer. 11 (2011) 411–425.

G.R. Mundy, Metastasis to bone: causes, consequences and therapeutic opportuni- ties, Nat. Rev. Cancer 2 (2002) 584–593.

P. Hadijì, Cancer treatment-induced bone loss in women with breast cancer, Bonekey Rep. 4 (2015) 1–5.

G. Altendorf, N.K. Ibrahim, L. Objectives, Aromatase inhibitors in breast cancer: an overview, Oncologist 11 (2006) 553–562.

S. Gaillard, V. Stearns, Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management, Breast Cancer Res. 13 (2011) 1–11.

C. Cruciciu, D. Fumagalli, S.K. Saini, Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for pa- tient selection, Onco Targets Ther. 4 (2011) 1–11.

R. Ward, G. Morgan, D. Dalley, P. Kely, Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal bone, Bone Miner. 22 (1993) 87–94.

S. Martinkovich, D. Shah, S.L. Planey, J.A. Amott, Selective estrogen receptor modulators: tissue specificity and clinical utility, Clin. Interv. Aging. 9 (2014) 1437–1452.

P. Hadijì, M. Ziller, D.G. Kieback, M. Kalder, J. Kuck, et al., The effect of exemestane or tamoxifen on markers of bone turnover: results of a German sub- study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial, Breast 18 (2009) 159–164.

R. Eastell, J.E. Adams, R.E. Coleman, A. Howell, R.A. Hannon, J. Cuzick, Effect of Anastrozole on Bone Mineral Density : 5-Year Results From the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230, J. Clin. Oncol. 26 (2008) 1057–1065.

H. Michael, P. Härkönen, L. Kangas, H. Väänänen, T. Hentunen, Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro, Br. J. Pharmacol. 151 (2007) 384–395.

S. Migliaccio, M. Brana, G. Spera, The differential effects of bisphosphonates, SERMS (selective estrogen receptor modulators), and parathyroid hormone on bone remodeling in osteoporosis, Clin. Interv. Aging. 2 (2007) 55–64.

P. Lehenkari, V. Parikk, T.J. Rautiala, M. Weckstrom, J. Dahlund, P. Härkönen, et al., The effects of tamoxifen and toremifene on bone cells involve changes, J. Bone Miner. Res. 18 (2003) 473–481.

A.D. Anastasiakos, S.A. Polyne, P. Makra, A. Gkionisi, G. Sakellariou, M. Savvidis, et al., Circulating semaphorin 4D and plexin-B1 levels in postmenopausal women with low bone mass : the 3-month effect of zoleodronic acid, denosumab or ter- iparatide treatment, Expert Opin. Ther. Targets 8222 (2015) 299–306.